Mexico Cardiac Resynchronization Therapy Market

Mexico Cardiac Resynchronization Therapy Market Executive Summary

Mexico Cardiac Resynchronization Therapy Market valued at $72 Mn in 2022, projected to reach $108 Mn by 2030 with a 5.25% CAGR.

Cardiac resynchronization therapy (CRT) involves the use of a pacemaker to correct the heart's rhythm through a minor surgical procedure. Implanted beneath the skin, the CRT pacemaker is responsible for coordinating the timing between the upper (atria) and lower (ventricles) heart chambers, as well as synchronizing the left and right sides of the heart. This intervention is particularly crucial in cases of heart failure, where inadequate pumping results in fluid accumulation in the lungs and legs due to the asynchronous beating of the two lower chambers (ventricles). Additionally, in the presence of severe heart rhythm issues, a physician might suggest an implantable cardioverter-defibrillator (ICD), which can be combined with CRT therapy. The CRT device connects wires from the pacemaker to both sides of the heart, employing biventricular pacing to transmit electrical signals to the ventricles, ensuring coordinated contractions and optimizing overall heart function.

Cardiovascular disorders are the leading cause of mortality in Mexico, accounting for 141,619 deaths, with 30% occurring in people under 70. The prevalence of cardiovascular disease (CVD) in older patients with long-term type 2 diabetes, mostly treated in private clinics, was exceptionally high at 36.9%. Specific prevalence rates were 3.9% for cerebrovascular disease, 5.0% for peripheral arterial disease, 8.4% for heart failure, and 23.1% for coronary heart disease. The HEARTS project, initiated in 2020, aims to reduce death and disability from cardiovascular events by implementing efficient hypertension management and enhancing cardiovascular health nationwide.

Major medical device manufacturers are introducing advanced Cardiac Resynchronization Therapy (CRT) devices with notable features. Miniaturization reduces the invasiveness of implantation procedures, while multi-electrode leads to enhanced stimulation efficacy. Remote monitoring capabilities enable better patient follow-up and prompt intervention. Sophisticated algorithms and artificial intelligence-powered features allow for individualized therapy modifications, representing a significant advancement. Clinical trials for next-generation CRT technology are underway in Mexico, aiming to evaluate effectiveness in improving patient outcomes and increasing access to cutting-edge therapies.

Market Dynamics

Market Growth Drivers

Increasing Incidence of Heart Failure: The increasing number of heart failure cases in Mexico is driving the demand for advanced cardiac therapies as the population ages and lifestyles change. Hypertension, myocardial infarction, atrial fibrillation, and heart failure represented an expense of $11.2 Bn in Mexico. Cardiovascular diseases are the leading cause of death in Mexico, with 141,619 deaths, and hypertension affects 18.4% of the population over 20 years of age. The HEARTS initiative has been launched in Mexico to improve the prevention and control of hypertension at the primary care level.

Technological Advancements in CRT Devices: Ongoing advancements in CRT device technologies, such as miniaturization, multi-electrode leads, and artificial intelligence-powered features, attract healthcare providers and patients alike. The adoption of these cutting-edge technologies enhances the effectiveness of therapy and contributes to market growth.

Rising Awareness and Education: Growing awareness among healthcare professionals and the general public about the benefits of CRT for managing heart conditions fuels market growth. Education campaigns and initiatives by medical professionals and industry players contribute to increased acceptance and adoption of CRT therapies.

Market Restraints

Restricted Insurance Benefits: Limited insurance coverage in certain areas poses a challenge for medical procedures like CRT, potentially hindering the broad adoption of these therapeutic interventions. This constraint could result in restricted accessibility and affordability for patients seeking cardiac resynchronization therapy in those regions.

Regulatory Obstacles: The regulatory landscape in Mexico poses challenges for the CRT market, potentially impacting the timely approval and introduction of innovative devices and technologies. Navigating regulatory hurdles may require strategic considerations for market players seeking to establish a presence in the healthcare sector in Mexico.

Economic Factors: Economic challenges and constrained financial resources can hinder the affordability of Cardiac Resynchronization Therapy (CRT) devices and procedures, impacting both healthcare facilities and patients in Mexico.

Healthcare Policies and Regulatory Landscape

In Mexico, the oversight of healthcare policies and regulatory control over therapeutic drugs primarily falls under the responsibility of the Federal Committee for Protection against Sanitary Risk (COFEPRIS), a division of the Ministry of Health. COFEPRIS collaborates with the Ministry of Health to ensure the effectiveness, safety, and quality of medications. The National Cancer Institute (INCan) serves as a pivotal reference organization for cancer care, while the National Institute of Public Health (INSP) contributes to the scientific foundation for healthcare decisions. The Mexican Social Security Institute (IMSS) influences drug accessibility and usage regulations for insured individuals, and the General Health Council provides guidance on health-related matters. Additionally, risk evaluation and management are facilitated by the National Commission for Protection against Health Risks (CONARIS).

Competitive Landscape

Key Players

• Abbott
• Boston Scientific
• Medtronic
• Siemens Healthineers
• Johnson & Johnson
• Biotronik
• LivaNova
• MicroPort
• Sorin Group
• St. Jude Medical